Artículos del autor

solaci

Day 2

PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized...
solaci -
Day 3

ALCADIA: An intra-myocardial injection of autologous cardiac derived stem cells improves ventricular function in patients with ischemic cardiomyopathy.

This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction...
solaci -
Day 2

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are...
solaci -
Day 2

Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.

Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite...
solaci -
Day 2

DALCETRAPIB: Dalcetrabib for the treatment of ACS

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased...
solaci -
Day 2

FORWARD Trial: Use of Omega 3 to prevent recurring atrial fibrillation

Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation...
solaci -
Day 2

OPERA Trial: Use of Omega 3 to prevent post-operative atrial fibrillation

Atrial fibrillation (AF) prolongues post-operative central vascular surgery, increasing morbidity and costs. Though smaller, a few trials...
solaci -
Day 2

UMPIRE Trial: the polypill proves effective in treating high risk patients.

A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients...
solaci -